Study of MR-proADM as a biomarker for kidney and liver transplant
Part of Digestive system, Immune system & allergy, Kidney & urinary clinical trials.
This trial is testing a simple blood biomarker called MR-proADM to see if it can help doctors detect early signs of transplant rejection or poor kidney function after a kidney or liver transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to receive or have just received a kidney transplant.
- You are scheduled to receive or have just received a liver transplant.
- This is your first transplant (not a repeat transplant).
- You are receiving only one organ (not a kidney and liver together, or a kidney and pancreas together).
- Your need for a transplant is not due to an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses magnetic resonance imaging (MRI) to see how well a transplanted kidney is working and how it affects your body's metabolism. It aims to find a noninvasive way to monitor kidney health without needing a biopsy.
This study looks at kidney transplant patients who are getting a kidney biopsy for usual clinical reasons. It tests whether special blood test results (from a sample taken as part of the study) can help spot transplant kidney problems earlier or more accurately.
This study checks whether a special blood test can help detect heart transplant rejection or problems by comparing it to biopsy results. It may help your care team monitor your transplant with less guesswork.
This study follows older people who received a kidney transplant and are taking a specific immune-suppressing medicine plan (Advagraf/tacrolimus once daily plus mycophenolate and steroids). It may help researchers understand outcomes in real-world patients who match these medication and immune-risk criteria.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
This study tests if a special MRI (without dye) can accurately measure how well a transplanted kidney is working. It is for people who have received a kidney transplant or a combined kidney-pancreas transplant, and for living donors.
Hear when a new Kidney Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.